$AMGN Headlines
Post# of 103171
Posted On: 11/20/2014 10:37:11 AM
$AMGN Headlines
Amgen's stock drops after trial misses secondary endpoint
9:20 a.m. Nov. 4, 2014
- Tomi Kilgore
Amgen's stock drops 2% in premarket trade
9:07 a.m. Nov. 4, 2014
- Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint
9:06 a.m. Nov. 4, 2014
- Tomi Kilgore
Facebook, Gilead shares fall after hours
6:14 p.m. Oct. 28, 2014
- Sue Chang
Amgen, under investor pressure, outlines strategy
10:05 a.m. Oct. 28, 2014
- MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans
9:07 a.m. Oct. 28, 2014
- Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans
8:55 a.m. Oct. 28, 2014
- Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln
8:54 a.m. Oct. 28, 2014
- Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08
8:53 a.m. Oct. 28, 2014
- Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018
8:52 a.m. Oct. 28, 2014
- Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015
8:52 a.m. Oct. 28, 2014
- Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015
8:51 a.m. Oct. 28, 2014
- Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks
8:35 a.m. Oct. 28, 2014
- Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid
8:43 p.m. Oct. 27, 2014
- Philip van Doorn
Newscast: Stocks mixed -- barely
6:46 p.m. Oct. 27, 2014
- MarketWatch
Twitter shares drop in wake of quarterly results
5:07 p.m. Oct. 27, 2014
- Sue Chang
Amgen posts strong results on higher sales
4:57 p.m. Oct. 27, 2014
- MarketWatch.com
Updates, advisories and surprises
4:31 p.m. Oct. 27, 2014
- MarketWatch
Amgen net drops, but adjusted earnings beat views
4:14 p.m. Oct. 27, 2014
- Russ Britt
Amgen GAAP net of $1.61 is below $1.81 view
4:06 p.m. Oct. 27, 2014
- Russ Britt
Global drug tab will breach trillion dollar mark this year
7:41 a.m. Today7:41 a.m. Nov. 20, 2014
- Seeking Alpha
Stocks Boosted by Merck’s Vytorin Data
7:25 a.m. Today7:25 a.m. Nov. 20, 2014
- Barrons.com
Positive clinical trial results for alirocumab presented at AHA meeting
12:35 p.m. Nov. 19, 2014
- Seeking Alpha
Hottest Healthcare Stocks Now – ACOR CBPO CELG AMGN
12:00 p.m. Nov. 19, 2014
- InvestorPlace.com
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog
11:23 a.m. Nov. 19, 2014
- Zacks.com
#PreMarket Primer: Wednesday, November 19: Burst Of Cold Creates Chaos In New York
6:50 a.m. Nov. 19, 2014
- benzinga.com
#PreMarket Primer: Wednesday, November 19: Burst Of Cold Creates Chaos In New York
6:50 a.m. Nov. 19, 2014
- benzinga.com
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
1:00 a.m. Nov. 19, 2014
- Zacks.com
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
1:00 a.m. Nov. 19, 2014
- Zacks.com
Gilead's Value Without Its Hep C Franchise
4:07 p.m. Nov. 18, 2014
- Seeking Alpha
Zetia Shows Modest Benefit in Reducing Heart Attacks
5:26 p.m. Nov. 17, 2014
- The Wall Street Journal Interactive Edition
Merck Drug Works: Vytorin Study Proves Successful
12:35 p.m. Nov. 17, 2014
- Investors Business Daily
3 Stocks Moving The Drugs Industry Upward
12:03 p.m. Nov. 17, 2014
- TheStreet.com
Jana Partners 13F Filing Shows Moves In Alibaba & Other Big Names
10:34 a.m. Nov. 14, 2014
- benzinga.com
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
9:23 a.m. Nov. 14, 2014
- Seeking Alpha
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
5:10 p.m. Nov. 13, 2014
- Zacks.com
Amgen Shares Consolidating Ahead Of More Gains?
12:25 p.m. Nov. 13, 2014
- benzinga.com
3 Stocks Underperforming Today In The Drugs Industry
12:06 p.m. Nov. 13, 2014
- TheStreet.com
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
9:52 a.m. Nov. 13, 2014
- Seeking Alpha
10 Must-Own Stocks With Great Earnings, Sales and Guidance
12:15 a.m. Nov. 13, 2014
- InvestorPlace.com
Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel
8:01 a.m. Nov. 19, 2014
- BusinessWire - BZX
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels
4:00 p.m. Nov. 18, 2014
- PR Newswire - PRF
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
4:05 p.m. Nov. 17, 2014
- GlobeNewswire
Amgen To Present At The Jefferies Global Healthcare Conference
4:15 p.m. Nov. 14, 2014
- PR Newswire - PRF
Critical Alerts For Caesars Entertainment, Orexigen Therapeutics, Amazon.com, Toyota Motor and Amgen Released By InvestorsObserver
9:31 a.m. Nov. 13, 2014
- PR Newswire - PRF
Biothera Names Carey Anderson VP of Regulatory Affairs
9:30 a.m. Nov. 13, 2014
- BusinessWire - BZX
Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions
4:35 p.m. Nov. 12, 2014
- PR Newswire - PRF
Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab
4:01 p.m. Nov. 12, 2014
- PR Newswire - PRF
The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide
9:00 a.m. Nov. 12, 2014
- PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
4:01 p.m. Nov. 11, 2014
- PR Newswire - PRF
Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth
2:24 p.m. Nov. 10, 2014
- PR Newswire - PRF
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
9:23 a.m. Nov. 10, 2014
- ACCESSWIRE
FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab
9:15 a.m. Nov. 10, 2014
- PR Newswire - PRF
Ziarco Raises $33.1 Million in Series B Financing
7:01 a.m. Nov. 10, 2014
- GlobeNewswire
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
8:50 a.m. Nov. 7, 2014
- PR Newswire - PRF
Amgen To Present At The Credit Suisse Annual Healthcare Conference
4:30 p.m. Nov. 6, 2014
- PR Newswire - PRF
Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014
4:01 p.m. Nov. 6, 2014
- PR Newswire - PRF
Cloud Pharmaceuticals Announces World-Class Board of Directors
8:00 a.m. Nov. 5, 2014
- PR Newswire - PRF
Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer
9:00 a.m. Nov. 4, 2014
- PR Newswire - PRF
Karyopharm Appoints J. Scott Garland to Its Board of Directors
7:00 a.m. Nov. 4, 2014
- GlobeNewswire
Amgen's stock drops after trial misses secondary endpoint
9:20 a.m. Nov. 4, 2014
- Tomi Kilgore
Amgen's stock drops 2% in premarket trade
9:07 a.m. Nov. 4, 2014
- Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint
9:06 a.m. Nov. 4, 2014
- Tomi Kilgore
Facebook, Gilead shares fall after hours
6:14 p.m. Oct. 28, 2014
- Sue Chang
Amgen, under investor pressure, outlines strategy
10:05 a.m. Oct. 28, 2014
- MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans
9:07 a.m. Oct. 28, 2014
- Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans
8:55 a.m. Oct. 28, 2014
- Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln
8:54 a.m. Oct. 28, 2014
- Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08
8:53 a.m. Oct. 28, 2014
- Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018
8:52 a.m. Oct. 28, 2014
- Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015
8:52 a.m. Oct. 28, 2014
- Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015
8:51 a.m. Oct. 28, 2014
- Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks
8:35 a.m. Oct. 28, 2014
- Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid
8:43 p.m. Oct. 27, 2014
- Philip van Doorn
Newscast: Stocks mixed -- barely
6:46 p.m. Oct. 27, 2014
- MarketWatch
Twitter shares drop in wake of quarterly results
5:07 p.m. Oct. 27, 2014
- Sue Chang
Amgen posts strong results on higher sales
4:57 p.m. Oct. 27, 2014
- MarketWatch.com
Updates, advisories and surprises
4:31 p.m. Oct. 27, 2014
- MarketWatch
Amgen net drops, but adjusted earnings beat views
4:14 p.m. Oct. 27, 2014
- Russ Britt
Amgen GAAP net of $1.61 is below $1.81 view
4:06 p.m. Oct. 27, 2014
- Russ Britt
Global drug tab will breach trillion dollar mark this year
7:41 a.m. Today7:41 a.m. Nov. 20, 2014
- Seeking Alpha
Stocks Boosted by Merck’s Vytorin Data
7:25 a.m. Today7:25 a.m. Nov. 20, 2014
- Barrons.com
Positive clinical trial results for alirocumab presented at AHA meeting
12:35 p.m. Nov. 19, 2014
- Seeking Alpha
Hottest Healthcare Stocks Now – ACOR CBPO CELG AMGN
12:00 p.m. Nov. 19, 2014
- InvestorPlace.com
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog
11:23 a.m. Nov. 19, 2014
- Zacks.com
#PreMarket Primer: Wednesday, November 19: Burst Of Cold Creates Chaos In New York
6:50 a.m. Nov. 19, 2014
- benzinga.com
#PreMarket Primer: Wednesday, November 19: Burst Of Cold Creates Chaos In New York
6:50 a.m. Nov. 19, 2014
- benzinga.com
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
1:00 a.m. Nov. 19, 2014
- Zacks.com
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
1:00 a.m. Nov. 19, 2014
- Zacks.com
Gilead's Value Without Its Hep C Franchise
4:07 p.m. Nov. 18, 2014
- Seeking Alpha
Zetia Shows Modest Benefit in Reducing Heart Attacks
5:26 p.m. Nov. 17, 2014
- The Wall Street Journal Interactive Edition
Merck Drug Works: Vytorin Study Proves Successful
12:35 p.m. Nov. 17, 2014
- Investors Business Daily
3 Stocks Moving The Drugs Industry Upward
12:03 p.m. Nov. 17, 2014
- TheStreet.com
Jana Partners 13F Filing Shows Moves In Alibaba & Other Big Names
10:34 a.m. Nov. 14, 2014
- benzinga.com
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
9:23 a.m. Nov. 14, 2014
- Seeking Alpha
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
5:10 p.m. Nov. 13, 2014
- Zacks.com
Amgen Shares Consolidating Ahead Of More Gains?
12:25 p.m. Nov. 13, 2014
- benzinga.com
3 Stocks Underperforming Today In The Drugs Industry
12:06 p.m. Nov. 13, 2014
- TheStreet.com
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
9:52 a.m. Nov. 13, 2014
- Seeking Alpha
10 Must-Own Stocks With Great Earnings, Sales and Guidance
12:15 a.m. Nov. 13, 2014
- InvestorPlace.com
Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel
8:01 a.m. Nov. 19, 2014
- BusinessWire - BZX
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels
4:00 p.m. Nov. 18, 2014
- PR Newswire - PRF
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
4:05 p.m. Nov. 17, 2014
- GlobeNewswire
Amgen To Present At The Jefferies Global Healthcare Conference
4:15 p.m. Nov. 14, 2014
- PR Newswire - PRF
Critical Alerts For Caesars Entertainment, Orexigen Therapeutics, Amazon.com, Toyota Motor and Amgen Released By InvestorsObserver
9:31 a.m. Nov. 13, 2014
- PR Newswire - PRF
Biothera Names Carey Anderson VP of Regulatory Affairs
9:30 a.m. Nov. 13, 2014
- BusinessWire - BZX
Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions
4:35 p.m. Nov. 12, 2014
- PR Newswire - PRF
Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab
4:01 p.m. Nov. 12, 2014
- PR Newswire - PRF
The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide
9:00 a.m. Nov. 12, 2014
- PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
4:01 p.m. Nov. 11, 2014
- PR Newswire - PRF
Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth
2:24 p.m. Nov. 10, 2014
- PR Newswire - PRF
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
9:23 a.m. Nov. 10, 2014
- ACCESSWIRE
FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab
9:15 a.m. Nov. 10, 2014
- PR Newswire - PRF
Ziarco Raises $33.1 Million in Series B Financing
7:01 a.m. Nov. 10, 2014
- GlobeNewswire
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
8:50 a.m. Nov. 7, 2014
- PR Newswire - PRF
Amgen To Present At The Credit Suisse Annual Healthcare Conference
4:30 p.m. Nov. 6, 2014
- PR Newswire - PRF
Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014
4:01 p.m. Nov. 6, 2014
- PR Newswire - PRF
Cloud Pharmaceuticals Announces World-Class Board of Directors
8:00 a.m. Nov. 5, 2014
- PR Newswire - PRF
Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer
9:00 a.m. Nov. 4, 2014
- PR Newswire - PRF
Karyopharm Appoints J. Scott Garland to Its Board of Directors
7:00 a.m. Nov. 4, 2014
- GlobeNewswire
(0)
(0)